- Home
- CLW vs IVA Comparison
CLW vs IVA Comparison
Compare CLW & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- IVA
- Stock Information
- Founded
- CLW 2005
- IVA 2011
- Country
- CLW United States
- IVA France
- Employees
- CLW N/A
- IVA N/A
- Industry
- CLW Paper
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- CLW Basic Materials
- IVA Health Care
- Exchange
- CLW Nasdaq
- IVA Nasdaq
- Market Cap
- CLW 348.3M
- IVA 359.6M
- IPO Year
- CLW N/A
- IVA 2020
- Fundamental
- Price
- CLW $22.01
- IVA $5.57
- Analyst Decision
- CLW Buy
- IVA Strong Buy
- Analyst Count
- CLW 1
- IVA 6
- Target Price
- CLW $36.00
- IVA $15.33
- AVG Volume (30 Days)
- CLW 197.2K
- IVA 71.1K
- Earning Date
- CLW 11-03-2025
- IVA 09-26-2025
- Dividend Yield
- CLW N/A
- IVA N/A
- EPS Growth
- CLW 345.10
- IVA N/A
- EPS
- CLW 12.12
- IVA N/A
- Revenue
- CLW $1,550,400,000.00
- IVA $14,591,573.00
- Revenue This Year
- CLW $12.75
- IVA $80.35
- Revenue Next Year
- CLW $1.60
- IVA N/A
- P/E Ratio
- CLW $1.76
- IVA N/A
- Revenue Growth
- CLW 34.73
- IVA N/A
- 52 Week Low
- CLW $20.84
- IVA $1.53
- 52 Week High
- CLW $33.57
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- CLW 42.70
- IVA 62.61
- Support Level
- CLW $21.08
- IVA $5.21
- Resistance Level
- CLW $21.92
- IVA $6.10
- Average True Range (ATR)
- CLW 0.61
- IVA 0.41
- MACD
- CLW 0.27
- IVA 0.07
- Stochastic Oscillator
- CLW 72.22
- IVA 61.04
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.